Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Insulin detemir + human soluble insulin** is a combination of two injectable insulin preparations for the management of diabetes mellitus. **Insulin detemir** is a long-acting human insulin analogue, produced by recombinant DNA technology, modified to bind albumin and thereby exhibit a slow absorption and prolonged activity. **Human soluble insulin** is a short-acting insulin, used to manage postprandial glucose elevations. This combination, though more commonly available as separate injections rather than fixed-dose combos, is designed to mimic both basal and prandial insulin secretion, providing improved blood glucose control in patients with type 1 and type 2 diabetes. Both components act as agonists of the insulin receptor, facilitating glucose uptake and utilization throughout the body.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on insulin detemir + human soluble insulin.